Skip to main content

FibroScan continues to solidify our position as the foundation for the non-invasive assessment of liver disease


Echosens innovative FibroScan technology is among the forefront of non-invasive technologies, further exemplified by our inclusion in 159 total abstract presentations, eight of which receiving an exemplary award from the AASLD. No other technology is referenced as frequently as FibroScan, the non-invasive, pain free, assessment for liver health.

In recent years HCV had been the most studied disease in the field of Elastography with over 2,000 peer reviewed publications. With the new NAFLD-NASH epidemic, the 2019 AASLD meeting has marked the first year ever that more abstracts include FibroScan for the study of NAFLD-NASH than HCV, with increasing emphasis on the importance of our CAP™  measurement.

Echosens has created a curated selection of FibroScan abstracts in PDF format for your convenience. To download the 2019 AASLD FibroScan abstract booklet, please click on the link below.

2019 AASLD FibroScan Abstracts

Visit booth #401 for a live demonstration of FibroScan


At this years liver meeting, Echosens will be showcasing our different FibroScan systems, including the FibroScan Compact & mini+, the latest in portable, non-invasive tools for assessing liver health.

We will also feature our latest communication products designed to streamline your FibroScan workflow and introduce our brand new FibroScan based scores.

Technician using the FibroScan Mini+ 430 to test a female patient who is lying on a table.